Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Resistant hypertension accelerates hypertension-mediated organ damage and is associated with increased cardiovascular risk and mortality. Previous studies have shown that resistant hypertension is more prevalent among overweight and obese individuals. Notably, large randomized controlled trials have reported blood pressure-lowering effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), suggesting that GLP-1RAs may represents a promising therapeutic option in this population. This study aims to compare the effectiveness of GLP-1RAs (semaglutide and tirzepatide) and mineralocorticoid receptor antagonists (MRAs, spironolactone and eplerenone) in reducing major adverse cardiovascular effect (MACE) among individuals with resistant hypertension.
The comparative effectiveness study included adults with Body-Mass-Index (BMI) ≥ 27 kg/m2 and resistant hypertension identified from TriNetX database who initiated treatment between June 1, 2017, and March 31, 2025. TriNetX database contains de-identified individual-level derived from electronic medical records of participating healthcare organizations. The primary outcome was MACE, including all-cause mortality during the 2-year follow-up period. The secondary outcomes were incident cardiovascular events, all-cause mortality, and changes in systolic blood pressure and BMI. Propensity score matching was employed to construct comparable cohorts of GLP-1RA and MRA users. Analyses were conducted using targeted learning within a trial emulation framework.
12,484 participants (6242 GLP-1RAs users: mean [SD] age, 58.6 [10.7] years, 50.3% female; 6242 MRAs users: mean [SD] age, 58.6 [11.5] years, 50.5% female) were included in the analysis after propensity score matching. After a mean (SD) follow-up of 15.5 (9.3) months, 297 patients (4.6%) in the GLP-1RAs cohort and 458 patients (7.3%) in the MRAs cohort experienced MACE. Compared to MRAs treatment, GLP-1RAs treatment was associated with significant lower risk of MACE (HR 0.68, 95%CI [0.59 - 0.79]), all-cause mortality (HR 0.33, 95%CI [0.22 - 0.49]), and incident cardiovascular events (HR 0.71, 95%CI [0.54 - 0.94]). GLP-1RAs treatment was also associated with greater weight loss (BMI) (GLP1-1RAs: -1.7 kg/m2, 95%CI [-2.2 to -1.8]; MRAs: -0.6 kg/m2, 95%CI [-1.0 to -0.2]). The systolic blood pressure-lowering effect was comparable between the two cohorts (GLP1-1RAs: -3.9 mmHg, 95%CI [-5.2 to -2.6]; MRAs: -5.1 mmHg, 95%CI [-6.3 to -3.9]).
In this study, GLP-1RAs treatment was associated with a significantly lower risk of MACE, while demonstrating a comparable blood pressure-lowering effect to MRAs treatment. These findings underscore the potential benefit of integrating GLP-1RAs into the standard of care for obese patients with resistant hypertension.
